
## Xiangsheng Zuo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6507658/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Translational Medicine, 2015, 4, 1033-1043.	1.6	474
2	The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-Â to induce apoptosis in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9968-9973.	3.3	217
3	The Role of CD44 and Cancer Stem Cells. Methods in Molecular Biology, 2018, 1692, 31-42.	0.4	138
4	KLF4 Is Essential for Induction of Cellular Identity Change and Acinar-to-Ductal Reprogramming during Early Pancreatic Carcinogenesis. Cancer Cell, 2016, 29, 324-338.	7.7	123
5	The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor. International Journal of Molecular Sciences, 2018, 19, 3339.	1.8	113
6	Targeted Genetic Disruption of Peroxisome Proliferator–Activated Receptor-Î′ and Colonic Tumorigenesis. Journal of the National Cancer Institute, 2009, 101, 762-767.	3.0	74
7	Metastasis regulation by PPARD expression in cancer cells. JCI Insight, 2017, 2, e91419.	2.3	58
8	KLF4-Mediated Suppression of CD44 Signaling Negatively Impacts Pancreatic Cancer Stemness and Metastasis. Cancer Research, 2016, 76, 2419-2431.	0.4	56
9	Profiling Lipoxygenase Metabolism in Specific Steps of Colorectal Tumorigenesis. Cancer Prevention Research, 2010, 3, 829-838.	0.7	52
10	ALOX15 as a suppressor of inflammation and cancer: Lost in the link. Prostaglandins and Other Lipid Mediators, 2017, 132, 77-83.	1.0	47
11	Potentiation of Colon Cancer Susceptibility in Mice by Colonic Epithelial PPAR-δ β Overexpression. Journal of the National Cancer Institute, 2014, 106, dju052.	3.0	42
12	Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Research, 2019, 79, 954-969.	0.4	41
13	Effects of Gut-Targeted 15-LOX-1 Transgene Expression on Colonic Tumorigenesis in Mice. Journal of the National Cancer Institute, 2012, 104, 709-716.	3.0	37
14	15â€Lipoxygenaseâ€l suppression of colitisâ€associated colon cancer through inhibition of the ILâ€6/STAT3 signaling pathway. FASEB Journal, 2015, 29, 2359-2370.	0.2	36
15	Mechanistic Contribution of Ubiquitous 15-Lipoxygenase-1 Expression Loss in Cancer Cells to Terminal Cell Differentiation Evasion. Cancer Prevention Research, 2011, 4, 1961-1972.	0.7	35
16	DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression. Clinical Cancer Research, 2017, 23, 5585-5597.	3.2	34
17	PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology, 2019, 157, 163-178.	0.6	34
18	Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nature Communications, 2022, 13, 2665.	5.8	25

XIANGSHENG ZUO

#	Article	IF	CITATIONS
19	Eicosanoid profiling in colon cancer: Emergence of a pattern. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 139-143.	1.0	20
20	Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: How to aim?. Biochemical Pharmacology, 2013, 85, 607-611.	2.0	19
21	BMP feed-forward loop promotes terminal differentiation in gastric glands and is interrupted by H. pylori-driven inflammation. Nature Communications, 2022, 13, 1577.	5.8	19
22	Suppression of Membranous LRP5 Recycling, Wnt/β-Catenin Signaling, and Colon Carcinogenesis by 15-LOX-1 Peroxidation of Linoleic Acid in PI3P. Cell Reports, 2020, 32, 108049.	2.9	18
23	Vitamin D: Promises on the Horizon and Challenges Ahead for Fighting Pancreatic Cancer. Cancers, 2021, 13, 2716.	1.7	10
24	Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. International Journal of Molecular Sciences, 2022, 23, 1645.	1.8	4
25	Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis. Cancer Prevention Research, 2022, 15, 217-223.	0.7	3